IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting
Helicobacter pylori infection is considered to be a risk factor for gastric cancer. A high prevalence of H. pylori infection and high gastric‐cancer incidence are characteristic of the Estonian population. To evaluate the relationship between these 2 events, we studied the seroprevalence of H. pylor...
Gespeichert in:
| Veröffentlicht in: | International journal of cancer 1996-07, Vol.67 (1), p.1-5 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | International journal of cancer |
| container_volume | 67 |
| creator | Klaamas, Kersti Held, Maria Wadström, Torkel Lipping, Agu Kurtenkov, Oleg |
| description | Helicobacter pylori infection is considered to be a risk factor for gastric cancer. A high prevalence of H. pylori infection and high gastric‐cancer incidence are characteristic of the Estonian population. To evaluate the relationship between these 2 events, we studied the seroprevalence of H. pylori in gastric cancer patients (n = 182) and in healthy blood donors (n = 306). A relative anti‐H. pylori IgG antibody activity, as detected by ELISA and immunoblot patterns, was correlated with age, stage of the disease and tumor morphology. A significantly higher H. pylori seroprevalence was found in patients in the early stages of tumor development compared with both advanced cancer patients and controls. No significant difference in H. pylori seroprevalence between patients with the intestinal and diffuse types of tumor growth was observed. A decline in the recognition of putatively cross‐reacting (33–66 kDa) antigens was noted in the cancer group. The response to vacuolating toxin‐related 85‐kDa and CagA 120‐kDa protein antigens was not altered and was observed more often in the younger group of cancer patients. © 1996 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/(SICI)1097-0215(19960703)67:1<1::AID-IJC1>3.0.CO;2-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_78137826</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78137826</sourcerecordid><originalsourceid>FETCH-LOGICAL-p3431-ee900825264d00b3fc2ef968bd326b0c0e327770f6e91f2d91325058deb35a7f3</originalsourceid><addsrcrecordid>eNqFkVFr2zAQx8XY6LJuH2GghzHaB2cnyZbsrAyC17UegTy0exayfc40bNmzFEr66WuTLK9DD4f4_-4O7kfIDYMlA-Bfrh6KvLhmkKkIOEuuWJZJUCCupVqxG7ZarYvvUfEzZ9_EEpb59iuP4BVZnBtek8U0BiLFhHxL3nn_B4CxBOILcpHKDBJQC_Jc7O6o7bq9QzqiH3rnkYae3mNrq740VcCRDoe2Hy01LtgdOk-to4MJFl3w9MmG33RnfBhtRSvjqok3ntbYWIc1LQ_0dlM8rKfm-rinL9s-BOt278mbxrQeP5zqJfn14_Yxv48227siX2-iQcSCRYgZQMoTLuMaoBRNxbHJZFrWgssSKkDBlVLQSMxYw-uMCZ5AktZYisSoRlySz8e5w9j_3aMPurO-wrY1Dvu91yplQqVc_hdkEtI0Az6BH0_gvuyw1sNoOzMe9OmqU_7plBtfmbYZp7NYf8YEi5mM5zGPR-zJtng4xwz07F_P-vVsU8829T_9WirNpjfZ17N9LTTofKv5VOa_eAHUdKbu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16088902</pqid></control><display><type>article</type><title>IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Klaamas, Kersti ; Held, Maria ; Wadström, Torkel ; Lipping, Agu ; Kurtenkov, Oleg</creator><creatorcontrib>Klaamas, Kersti ; Held, Maria ; Wadström, Torkel ; Lipping, Agu ; Kurtenkov, Oleg</creatorcontrib><description>Helicobacter pylori infection is considered to be a risk factor for gastric cancer. A high prevalence of H. pylori infection and high gastric‐cancer incidence are characteristic of the Estonian population. To evaluate the relationship between these 2 events, we studied the seroprevalence of H. pylori in gastric cancer patients (n = 182) and in healthy blood donors (n = 306). A relative anti‐H. pylori IgG antibody activity, as detected by ELISA and immunoblot patterns, was correlated with age, stage of the disease and tumor morphology. A significantly higher H. pylori seroprevalence was found in patients in the early stages of tumor development compared with both advanced cancer patients and controls. No significant difference in H. pylori seroprevalence between patients with the intestinal and diffuse types of tumor growth was observed. A decline in the recognition of putatively cross‐reacting (33–66 kDa) antigens was noted in the cancer group. The response to vacuolating toxin‐related 85‐kDa and CagA 120‐kDa protein antigens was not altered and was observed more often in the younger group of cancer patients. © 1996 Wiley‐Liss, Inc.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/(SICI)1097-0215(19960703)67:1<1::AID-IJC1>3.0.CO;2-0</identifier><identifier>PMID: 8690507</identifier><identifier>CODEN: IJCNAW</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antibodies, Bacterial - blood ; Antigens, Bacterial - immunology ; Bacterial Proteins - immunology ; Biological and medical sciences ; Enzyme-Linked Immunosorbent Assay ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Helicobacter pylori ; Helicobacter pylori - immunology ; Humans ; Immunoblotting ; Immunoglobulin M - blood ; Male ; Medical sciences ; Middle Aged ; Molecular Weight ; Neoplasm Staging ; Stomach Neoplasms - immunology ; Stomach Neoplasms - pathology ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Tumors</subject><ispartof>International journal of cancer, 1996-07, Vol.67 (1), p.1-5</ispartof><rights>Copyright © 1996 Wiley‐Liss, Inc.</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291097-0215%2819960703%2967%3A1%3C1%3A%3AAID-IJC1%3E3.0.CO%3B2-0$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291097-0215%2819960703%2967%3A1%3C1%3A%3AAID-IJC1%3E3.0.CO%3B2-0$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3141642$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8690507$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Klaamas, Kersti</creatorcontrib><creatorcontrib>Held, Maria</creatorcontrib><creatorcontrib>Wadström, Torkel</creatorcontrib><creatorcontrib>Lipping, Agu</creatorcontrib><creatorcontrib>Kurtenkov, Oleg</creatorcontrib><title>IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>Helicobacter pylori infection is considered to be a risk factor for gastric cancer. A high prevalence of H. pylori infection and high gastric‐cancer incidence are characteristic of the Estonian population. To evaluate the relationship between these 2 events, we studied the seroprevalence of H. pylori in gastric cancer patients (n = 182) and in healthy blood donors (n = 306). A relative anti‐H. pylori IgG antibody activity, as detected by ELISA and immunoblot patterns, was correlated with age, stage of the disease and tumor morphology. A significantly higher H. pylori seroprevalence was found in patients in the early stages of tumor development compared with both advanced cancer patients and controls. No significant difference in H. pylori seroprevalence between patients with the intestinal and diffuse types of tumor growth was observed. A decline in the recognition of putatively cross‐reacting (33–66 kDa) antigens was noted in the cancer group. The response to vacuolating toxin‐related 85‐kDa and CagA 120‐kDa protein antigens was not altered and was observed more often in the younger group of cancer patients. © 1996 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Bacterial - blood</subject><subject>Antigens, Bacterial - immunology</subject><subject>Bacterial Proteins - immunology</subject><subject>Biological and medical sciences</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Helicobacter pylori</subject><subject>Helicobacter pylori - immunology</subject><subject>Humans</subject><subject>Immunoblotting</subject><subject>Immunoglobulin M - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Weight</subject><subject>Neoplasm Staging</subject><subject>Stomach Neoplasms - immunology</subject><subject>Stomach Neoplasms - pathology</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Tumors</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkVFr2zAQx8XY6LJuH2GghzHaB2cnyZbsrAyC17UegTy0exayfc40bNmzFEr66WuTLK9DD4f4_-4O7kfIDYMlA-Bfrh6KvLhmkKkIOEuuWJZJUCCupVqxG7ZarYvvUfEzZ9_EEpb59iuP4BVZnBtek8U0BiLFhHxL3nn_B4CxBOILcpHKDBJQC_Jc7O6o7bq9QzqiH3rnkYae3mNrq740VcCRDoe2Hy01LtgdOk-to4MJFl3w9MmG33RnfBhtRSvjqok3ntbYWIc1LQ_0dlM8rKfm-rinL9s-BOt278mbxrQeP5zqJfn14_Yxv48227siX2-iQcSCRYgZQMoTLuMaoBRNxbHJZFrWgssSKkDBlVLQSMxYw-uMCZ5AktZYisSoRlySz8e5w9j_3aMPurO-wrY1Dvu91yplQqVc_hdkEtI0Az6BH0_gvuyw1sNoOzMe9OmqU_7plBtfmbYZp7NYf8YEi5mM5zGPR-zJtng4xwz07F_P-vVsU8829T_9WirNpjfZ17N9LTTofKv5VOa_eAHUdKbu</recordid><startdate>19960703</startdate><enddate>19960703</enddate><creator>Klaamas, Kersti</creator><creator>Held, Maria</creator><creator>Wadström, Torkel</creator><creator>Lipping, Agu</creator><creator>Kurtenkov, Oleg</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>19960703</creationdate><title>IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting</title><author>Klaamas, Kersti ; Held, Maria ; Wadström, Torkel ; Lipping, Agu ; Kurtenkov, Oleg</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p3431-ee900825264d00b3fc2ef968bd326b0c0e327770f6e91f2d91325058deb35a7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Bacterial - blood</topic><topic>Antigens, Bacterial - immunology</topic><topic>Bacterial Proteins - immunology</topic><topic>Biological and medical sciences</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Helicobacter pylori</topic><topic>Helicobacter pylori - immunology</topic><topic>Humans</topic><topic>Immunoblotting</topic><topic>Immunoglobulin M - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Weight</topic><topic>Neoplasm Staging</topic><topic>Stomach Neoplasms - immunology</topic><topic>Stomach Neoplasms - pathology</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Klaamas, Kersti</creatorcontrib><creatorcontrib>Held, Maria</creatorcontrib><creatorcontrib>Wadström, Torkel</creatorcontrib><creatorcontrib>Lipping, Agu</creatorcontrib><creatorcontrib>Kurtenkov, Oleg</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Klaamas, Kersti</au><au>Held, Maria</au><au>Wadström, Torkel</au><au>Lipping, Agu</au><au>Kurtenkov, Oleg</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>1996-07-03</date><risdate>1996</risdate><volume>67</volume><issue>1</issue><spage>1</spage><epage>5</epage><pages>1-5</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><coden>IJCNAW</coden><abstract>Helicobacter pylori infection is considered to be a risk factor for gastric cancer. A high prevalence of H. pylori infection and high gastric‐cancer incidence are characteristic of the Estonian population. To evaluate the relationship between these 2 events, we studied the seroprevalence of H. pylori in gastric cancer patients (n = 182) and in healthy blood donors (n = 306). A relative anti‐H. pylori IgG antibody activity, as detected by ELISA and immunoblot patterns, was correlated with age, stage of the disease and tumor morphology. A significantly higher H. pylori seroprevalence was found in patients in the early stages of tumor development compared with both advanced cancer patients and controls. No significant difference in H. pylori seroprevalence between patients with the intestinal and diffuse types of tumor growth was observed. A decline in the recognition of putatively cross‐reacting (33–66 kDa) antigens was noted in the cancer group. The response to vacuolating toxin‐related 85‐kDa and CagA 120‐kDa protein antigens was not altered and was observed more often in the younger group of cancer patients. © 1996 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8690507</pmid><doi>10.1002/(SICI)1097-0215(19960703)67:1<1::AID-IJC1>3.0.CO;2-0</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 1996-07, Vol.67 (1), p.1-5 |
| issn | 0020-7136 1097-0215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78137826 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Aged, 80 and over Antibodies, Bacterial - blood Antigens, Bacterial - immunology Bacterial Proteins - immunology Biological and medical sciences Enzyme-Linked Immunosorbent Assay Female Gastroenterology. Liver. Pancreas. Abdomen Helicobacter pylori Helicobacter pylori - immunology Humans Immunoblotting Immunoglobulin M - blood Male Medical sciences Middle Aged Molecular Weight Neoplasm Staging Stomach Neoplasms - immunology Stomach Neoplasms - pathology Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors |
| title | IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T23%3A12%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IgG%20immune%20response%20to%20Helicobacter%20pylori%20antigens%20in%20patients%20with%20gastric%20cancer%20as%20defined%20by%20ELISA%20and%20immunoblotting&rft.jtitle=International%20journal%20of%20cancer&rft.au=Klaamas,%20Kersti&rft.date=1996-07-03&rft.volume=67&rft.issue=1&rft.spage=1&rft.epage=5&rft.pages=1-5&rft.issn=0020-7136&rft.eissn=1097-0215&rft.coden=IJCNAW&rft_id=info:doi/10.1002/(SICI)1097-0215(19960703)67:1%3C1::AID-IJC1%3E3.0.CO;2-0&rft_dat=%3Cproquest_pubme%3E78137826%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16088902&rft_id=info:pmid/8690507&rfr_iscdi=true |